These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Greten H, Beil FU, Schneider J, Weisweiler P, Armstrong VW, Keller C, Klör HU, von Hodenberg E, Weidinger G, Eskötter H. Am J Med; 1994 Jun 06; 96(6A):55S-63S. PubMed ID: 8017468 [Abstract] [Full Text] [Related]
43. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ. Arch Intern Med; 1994 Nov 14; 154(21):2449-55. PubMed ID: 7979841 [Abstract] [Full Text] [Related]
44. Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention. Nash DT. Am J Cardiol; 1996 Sep 26; 78(6A):26-31. PubMed ID: 8875972 [Abstract] [Full Text] [Related]
45. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial. Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD. Am J Cardiol; 1995 Jul 13; 76(2):37A-40A. PubMed ID: 7604795 [Abstract] [Full Text] [Related]
46. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. Appel-Dingemanse S, Smith T, Merz M. J Clin Pharmacol; 2002 Mar 13; 42(3):312-8. PubMed ID: 11865968 [Abstract] [Full Text] [Related]
47. Hydroxymethylglutaryl coenzyme a reductase inhibition: fluvastatin, a clinical investigators' update. Introduction. Brown WV. Am J Cardiol; 1994 May 26; 73(14):1D-2D. PubMed ID: 8198017 [No Abstract] [Full Text] [Related]
48. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Fauler G, Abletshauser C, Erwa W, Löser R, Witschital K, März W. Int J Clin Pharmacol Ther; 2007 Jun 26; 45(6):328-34. PubMed ID: 17595890 [Abstract] [Full Text] [Related]
49. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. Winkler K, Ablethauser CB, Gimpelewicz C, Bortolini M, Isaacsohn JL. Clin Ther; 2007 Sep 26; 29(9):1987-2000. PubMed ID: 18035198 [Abstract] [Full Text] [Related]
50. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Am J Geriatr Pharmacother; 2007 Sep 26; 5(3):185-94. PubMed ID: 17996658 [Abstract] [Full Text] [Related]
51. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR. Am J Health Syst Pharm; 1995 Aug 01; 52(15):1639-45. PubMed ID: 7583826 [Abstract] [Full Text] [Related]
52. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Asberg A, Holdaas H. Expert Rev Cardiovasc Ther; 2004 Sep 01; 2(5):641-52. PubMed ID: 15350166 [Abstract] [Full Text] [Related]
53. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin]. Potier A, Dony A, Crapsky A, Ferry O, Piney D, Dufay E. Therapie; 2015 Sep 01; 70(6):541-4. PubMed ID: 26238127 [Abstract] [Full Text] [Related]
54. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Plans-Rubió P. Am J Cardiovasc Drugs; 2006 Sep 01; 6(3):177-88. PubMed ID: 16780391 [Abstract] [Full Text] [Related]
58. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Leu HB, Chen JW, Wu TC, Ding YA, Lin SJ, Charng MJ. Clin Cardiol; 2005 Sep 01; 28(9):423-8. PubMed ID: 16250265 [Abstract] [Full Text] [Related]